Home » Stocks » VRDN

Viridian Therapeutics, Inc. (VRDN)

Stock Price: $16.54 USD -0.44 (-2.59%)
Updated Feb 26, 2021 3:31 PM EST - Market closed
Market Cap 64.25M
Revenue (ttm) 1.88M
Net Income (ttm) -30.09M
Shares Out 3.72M
EPS (ttm) -10.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $16.54
Previous Close $16.98
Change ($) -0.44
Change (%) -2.59%
Day's Open 17.15
Day's Range 16.12 - 17.15
Day's Volume 28,954
52-Week Range 4.66 - 25.67


Hide News
24/7 Wall Street - 1 month ago

With the trading day about half over, the broad markets had pulled back on Monday.

Other stocks mentioned: AAPL, GOOG, GOOGL, ROKU, TSLA, BBBY, CRWD, DKS, LEVI, PLNT
GlobeNewsWire - 1 month ago

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics...

Other stocks mentioned: MGEN

About VRDN

Viridian Therapeutics, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found... [Read more...]

William Marshall
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, VRDN's revenue was $4.46 million, a decrease of -46.80% compared to the previous year's $8.39 million. Losses were -$41.87 million, 28.0% more than in 2018.

Financial Statements